<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/42CFR419.html">Part 419
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 419.62  Transitional pass-through payments: General rules.
                            </h3>
                            <p class="depth1"><em>(a)</em> General. CMS provides for additional payments under Secs. 419.64  and 419.66 for certain innovative medical devices, drugs, and  biologicals.</p><p class="depth1"><em>(b)</em> Budget neutrality. CMS establishes the additional payments under  Secs. 419.64 and 419.66 in a budget neutral manner.</p><p class="depth1"><em>(c)</em> Uniform prospective reduction of pass-through payments. </p><p class="depth2"><em>(1)</em> If  CMS estimates before the beginning of a calendar year that the total  amount of pass-through payments under Secs. 419.64 and 419.66 for the  year would exceed the applicable percentage (as described in paragraph  (c)(2) of this section) of the total amount of Medicare payments under  the outpatient prospective payment system. CMS will reduce, pro rata,  the amount of each of the additional payments under Secs. 419.64 and  419.66 for that year to ensure that the applicable percentage is not  exceeded.</p><p class="depth2"><em>(2)</em> The applicable percentages are as follows:</p><p class="depth3"><em>(i)</em> For a year before CY 2004, the applicable percentage is 2.5  percent.</p><p class="depth3"><em>(ii)</em> For 2004 and subsequent years, the applicable percentage is a  percentage specified by CMS up to (but not to exceed) 2.0 percent.</p><p class="depth1"><em>(d)</em> CY 2002 incorporated amount. For the portion of CY 2002 affected  by these rules, CMS incorporated 75 percent of the estimated pass- through costs (before the incorporation and any pro rata reduction) for  devices into the procedure APCs associated with these devices.  [66 FR 55856, 55865, Nov. 2, 2001; 67 FR 9568, Mar. 1, 2002]</p><p class="depth2">Effective Date Note: At 66 FR 55865, Nov. 2, 2001, Sec. 419.62 was  amended by adding paragraph (d), effective Jan. 1, 2002. At 66 FR 67494,  Dec. 31, 2001, the amendment was delayed indefinitely.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
